obesity drug news today glp-1 october 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford obesity drug news today glp-1

FLOW Trial: In T2DM patients with chronic kidney disease (CKD), semaglutide reduced the composite of kidney-disease progression or HF events by 27% (HR 0.73, 95% CI 0.540.98) alongside renal benefits [58]

Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al

We recognize the dual benefits of these medications, not only in improving glycemic control but also in aiding weight loss by promoting satiety and slowing gastric emptying

How Riddle & Riddle Injury Lawyers Can Help At Riddle & Riddle Injury Lawyers, we closely monitor major litigation developments that affect patients and families across the country

The highest risk for all complications was observed in patients who continued Ozempic use through surgery

This effect is most pronounced with short-acting agents such as exenatide twice daily and becomes attenuated (though not eliminated) with longer-acting formulations